Opioid Overdose Clinical Trial
Official title:
Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone
Verified date | October 2021 |
Source | Auburn University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Objectives: The purpose of this study was to assess the impact of the Empowering Community Pharmacists program on pharmacists' knowledge, perceived barriers, attitudes, confidence, and intentions regarding naloxone services implementation, as well as change in number of naloxone prescriptions dispensed. Methods: A 3-month pragmatic randomized controlled trial was conducted in 2018-2019. Alabama community pharmacists were recruited by email, phone, fax, and mailed postcards and randomized to intervention (monthly resources/reminders + educational webinar) or control (monthly resources/reminders + delayed educational webinar). Outcome measures were assessed via online surveys at baseline (T1), immediately post-intervention (T2), and 3-months post-intervention (T3), including: naloxone knowledge (percent correct); perceived barriers, attitudes, and confidence regarding naloxone services implementation (7-point Likert-type scale, 1=strongly disagree to 7=strongly agree); and number of naloxone prescriptions dispensed. Mean differences between control and intervention groups from T1-T3 were assessed using two-way mixed ANOVA and adjusted analyses were conducted using generalized estimating equations (GEE) with negative binomial distribution (alpha=0.05).
Status | Completed |
Enrollment | 55 |
Est. completion date | September 18, 2019 |
Est. primary completion date | September 18, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Registered pharmacists. - Employed at least 30 hours per week at a community pharmacy. - Employed at a community pharmacy located in one of 20 Alabama priority counties with the highest opioid overdose mortality rates. Exclusion Criteria: - Multiple pharmacists from the same pharmacy site. - Members of the stakeholder panel (from the formative phase of the study). |
Country | Name | City | State |
---|---|---|---|
United States | Auburn University Harrison School of Pharmacy | Auburn | Alabama |
Lead Sponsor | Collaborator |
---|---|
Auburn University | Agency for Healthcare Research and Quality (AHRQ) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in naloxone knowledge from baseline to immediately post-intervention and 3 months post-intervention | Knowledge about naloxone was measured via online survey. Knowledge was measured as percent correct on a 7-item index adapted from Williams' (2013) Opioid Overdose Knowledge Scale (OOKS). | 3 months: baseline (T1), immediately post-intervention (T2), and 3 months post-intervention (T3) | |
Primary | Change in perceived barriers from baseline to immediately post-intervention and 3 months post-intervention | Perceived barriers to adoption/implementation of pharmacy-based naloxone services was measured via online survey. Barriers (20-items) were measured using 7-point Likert-type scales (1=strongly disagree, 7=strongly agree) and informed by Nielsen et al (2016) and Williams' (2013) Opioid Overdose Attitude Scale (OOAS). | 3 months: baseline (T1), immediately post-intervention (T2), and 3 months post-intervention (T3) | |
Primary | Change in attitudes from baseline to immediately post-intervention and 3 months post-intervention | Attitudes regarding pharmacy-based naloxone services was measured via online survey. Attitudes (15-items) were measured using 7-point Likert-type scales (1=strongly disagree, 7=strongly agree) and informed by Nielsen et al (2016) and Williams' (2013) Opioid Overdose Attitude Scale (OOAS). | 3 months: baseline (T1), immediately post-intervention (T2), and 3 months post-intervention (T3) | |
Primary | Change in confidence from baseline to immediately post-intervention and 3 months post-intervention | Confidence in performing naloxone dispensing behaviors was measured via online survey. Confidence (10-items) was measured using 7-point Likert-type scales (1=strongly disagree, 7=strongly agree) and informed by Nielsen et al (2016) and Williams' (2013) Opioid Overdose Attitude Scale (OOAS). | 3 months: baseline (T1), immediately post-intervention (T2), and 3 months post-intervention (T3) | |
Primary | Change in intention from baseline to immediately post-intervention and 3 months post-intervention | Intention to dispense naloxone or perform naloxone services in the next three months was measured via online survey. The 5-item intention construct was measured using a 7-point Likert-type scale from 1=strongly disagree to 7=strongly agree and informed by an existing intention measure by Urmie et al (2007). | 3 months: baseline (T1), immediately post-intervention (T2), and 3 months post-intervention (T3) | |
Secondary | Change in number of naloxone prescriptions dispensed from baseline to 3 months post-intervention | The number of naloxone prescriptions dispensed over 3 months before and after the intervention was assessed via self-report at T1 and T3. Participants utilized national drug codes (NDCs) within their pharmacy dispensing software to identify naloxone dispensing information. | 3 months: baseline (T1) and 3 months post-intervention (T3) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04372238 -
The Rhode Island Prescription and Illicit Drug Study
|
N/A | |
Recruiting |
NCT03924505 -
Preventing Opioid Overdose Mortality in the United States
|
N/A | |
Completed |
NCT05219669 -
Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens
|
Phase 1 | |
Completed |
NCT04317053 -
Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program
|
Phase 3 | |
Not yet recruiting |
NCT06466005 -
UnityPhilly Response App for Overdose Reversal
|
||
Recruiting |
NCT04815590 -
Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
|
||
Active, not recruiting |
NCT05096429 -
Preventing Overdose Using Information and Data From the Environment
|
N/A | |
Suspended |
NCT05114460 -
Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal
|
Phase 2 | |
Recruiting |
NCT06238128 -
Opioid Rapid Response System: Naloxone Training in Communities
|
N/A | |
Completed |
NCT02662153 -
Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics
|
||
Active, not recruiting |
NCT05944133 -
Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD
|
||
Completed |
NCT05377255 -
Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults
|
Phase 1 | |
Recruiting |
NCT05877118 -
Improving Availability of Intranasal Naloxone
|
N/A | |
Recruiting |
NCT05072249 -
European Cohort Study of the Effectiveness of Take Home Naloxone
|
||
Withdrawn |
NCT05808881 -
Clinical Outcomes From Nalmefene
|
Phase 4 | |
Not yet recruiting |
NCT01622504 -
Naloxone Nasal Spray Pharmacokinetic Study
|
Phase 1 | |
Not yet recruiting |
NCT06429436 -
Vending Machine Naloxone Distribution for Your Community (VENDY)
|
Phase 4 | |
Completed |
NCT05506267 -
Development of a Tracheal Sound Sensor
|
||
Completed |
NCT02535494 -
Risks and Benefits of Naloxone Prescribing
|
N/A | |
Not yet recruiting |
NCT06408714 -
Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose
|
Phase 3 |